Semaglutide has been shown to promote significant weight loss, improve glycemic control in people with type 2 diabetes, and reduce the risk of cardiovascular disease
Key Clinical Findings from Rose Pharma Studies: Proven Appetite Suppression: Completed proof of concept study, demonstrated that ROSE-010 significantly reduces food consumption and slows gastric emptying Rapid Onset, Short Duration: Begins working within 20 minutes and clears within a few hours, minimizing side effects Reduced GI Side Effects: Unlike long-acting GLP-1s, ROSE-010s shorter half-life lowers the period of nausea and GI distress Improved Tolerability: Targets appetite without prolonged drug exposure, making it an ideal maintenance therapy Why the Market Needs ROSE-010 60-85% of GLP-1 patients need an effective weight loss maintenance strategy Current solutions focus on weight lossPeople need long-term weight loss management options ROSE-010 offers a flexible, meal-time approach to prevent weight regain Real-world data shows that long-term GLP-1 adherence is low yet patients need tools to sustain their progress
Orforglipron Developed by Eli Lilly, orforglipron mimics the GLP-1 hormone
Equal saline injections were administered for the sham group and OA group
Apr 2012;35(8):876-93
Widely utilized in cosmetic and therapeutic applications, GHK-Cu is valued for its anti-aging benefits, offering comprehensive skin rejuvenation and contributing to healthier, more youthful-looking skin
.jpg)
